Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the ...

Biogen said on Friday it has gained global rights to privately held Vanqua Bio's experimental drug for up to $1.06 billion to ...

Biogen and partner UCB recently announced upcoming presentations at the American College of Rheumatology 2025 conference highlighting positive Phase 3 data for dapirolizumab pegol in treating systemic ...

SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, today announced it will share four presentations highlighting new data about the ...

Announces Expiration Of Final Hedge Fund Warrants And Confirms Oct. 27 CVR Record Date. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced the expiration at 5 p.m. ET of 53,147 warrants ...

Bristol Myers Squibb have extended their research collaboration aimed at designing and optimizing small-molecule drugs for ...

During the webinar, Unbuzzd CEO John Duffy, Advisor Jason Sawyer, Medical Director Dr. Eric Hoskins, and Board Co-Chair Gerry David, former CEO of Celsius, will discuss the current investment ...

It’s baffling in hindsight to consider Ozzy Osbourne retiring in his mid-40s. Nevertheless, the Prince of Darkness took his first final bow at the conclusion of his 1992 No More Tours Tour in support ...

Q3 2025 Earnings Call October 24, 2025 8:30 AM EDTCompany ParticipantsThomas Larsen - Head of Investor RelationsPaul Hudson - CEO ...

Appointment reinforces ProMIS Neurosciences’ strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer’s program, PMN310 ...

Retinal inner layer thinning detected by OCT offers a promising biomarker for monitoring multiple sclerosis progression.

Now, by analyzing thousands of proteins found in the blood, scientists at UC San Francisco have created the clearest picture ...